Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V526 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MRKAd6 Trigene 0.5x10\^9 Ad6 vg |
| 2 | EXPERIMENTAL | MRKAd6 Trigene 0.5x10\^10 Ad6 vg |
| 3 | EXPERIMENTAL | MRKAd6 Trigene 0.5x10\^11 Ad6 vg |
| 4 | EXPERIMENTAL | MRKAd5 Trigene 0.5x10\^10 Ad5 vg |
| 5 | EXPERIMENTAL | MRKAd5 Trivalent 1.5x10\^10 Ad5 vg |
| 6 | EXPERIMENTAL | MRKAd5+6 Trigene 1x10\^9 Ad vg |
| 7 | EXPERIMENTAL | MRKAd5+6 Trigene 1x10\^10 Ad vg |
| 8 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| V526 | BIOLOGICAL | 0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26. |
| Comparator: Placebo to V526 | BIOLOGICAL | 0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26. |
Inclusion Criteria: * Subject has negative tests for HIV, Hepatitis B, and Hepatitis C within 60 days of injection * Subject agrees to use an acceptable method of birth control through week 52 of the study Exclusion Criteria: * Subject has been given immune globulin or blood products within 30 da...
V526 is an investigational monoclonal antibody being developed for HIV and HIV infections. It is currently in Phase 1 clinical development and is not approved by the FDA. The drug is being studied for its potential role in addressing HIV, a viral infection that affects the immune system.
V526 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody for HIV.
V526 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing for HIV.
V526 has one completed Phase 1 clinical trial registered under NCT00850616, titled "Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)." The trial enrolled 147 participants, was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
Yes, V526 is also known as MRKAd5+6 Trigene. The completed Phase 1 clinical trial NCT00850616 refers to the drug as MRKAd5+6 Trigene (V526), confirming that both names refer to the same investigational monoclonal antibody being developed for HIV.